Author(s):
Ahmed Alkhodri
Email(s):
ahmed-emad-alkhodri@wpu.edu.sy
DOI:
10.52711/0974-360X.2026.00240
Address:
Ahmed Alkhodri1,2,3*
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Wataniya Private University, Hama, Syria.
2Department of Industrial Pharmacy, LEM Pharma, Pharmaceutical Company, Hama, Syria.
3Department of Bio Pharmacy, Faculty of Pharmacy, Homs University, Homs, Syria.
*Corresponding Author
Published In:
Volume - 19,
Issue - 4,
Year - 2026
ABSTRACT:
Aim of this research was formulation matrix tablets of trimetazidine with extended release (ER), and evaluation the influence of different types and concentrations of polymers on release of drug in vitro. Six formulations F1 – F6 were manually designed by wet granulation using different proportions and amount of polymers. The formulations of ER matrix tablets (F1 – F6) were composed of using different polymers such as, hydroxypropyl methylcellulose (HPMC-?100?), hydroxypropyl cellulose high viscosity (HPCh), carboxymethyl cellulose (CMC), ethylcellulose (EC-10 cps), carbopol-940. All ER formulations contained polyvinylpyrrolidone (PVP-?30), microcrystalline cellulose (MCC), dibasic calcium phosphate and magnesium stearate. The PVP-?30 and magnesium stearate were used in a fixed quantity in all ER formulations. The effect of polymer viscosity, its proportion and co-formulation of polymeric excipients in prepared tablets on trimetazidine release from all formulations was studied. Data drug release in vitro was performed in phosphate buffer of pH 7.4 by analytical method, because cellulose polymers are insoluble in gastric fluid. The amount of released trimetazidine was calculated by preparing standard series in phosphate medium. Dissolution profile indicated that formulations F1 and F2 extended the drug release for 16h. Formulations F3 and F5 released 92.28%, 87.72% of their content during 12h respectively. While formulations F4 and F6 released 72.09%, 58.5% of their content within 16h consecutively, thus their effect can last for more than a day due to the high viscosity and amount of polymers. MS Excel was used to analyze the in vitro release kinetics profile data such as Zero-order, first order, Higuchi and Korsmeyer–Peppas models. However, formulations (F1, F2) containing polymers (HPMC -?100?, HPMC and EC) as a matrix former showed drug release as highest correlation coefficient (r2) values obtained when Korsmeyer-peppas model was applied (r2 = 0.9801 – 0.9713) respectively. Formulation F3 containing (HPMC and CMC) showed the highest correlation coefficient (r2) value when first order model was applied (r2 = 0.9885). While formulation (F5) containing hydrophobic polymer (EC-10cps) showed concentration-independent drug release as highest linearity was observed when zero-order model was applied (r2 = 0.8916). Whereas, formulations (F4, F6) containing (Carbopol-940, HPCh) as a matrix former showed the highest correlation coefficient (r2) values when higuchi-order model was applied (r2 = 0.9804, 0.9317) consecutively. Release mechanism of trimetazidine from all formulations was Case II relaxation mechanism (Erosion release). The present study showed that cellulosic derivatives polymers can be used successfully for developing and controlling directly release of matrix tablets formulation.
Cite this article:
Ahmed Alkhodri. Preparation, Evaluation and Development Trimetazidine Dihydrochloride Extended Release (ER) Tablets by Wet Granulation Method. Research Journal of Pharmacy and Technology. 2026;19(4):1675-0. doi: 10.52711/0974-360X.2026.00240
Cite(Electronic):
Ahmed Alkhodri. Preparation, Evaluation and Development Trimetazidine Dihydrochloride Extended Release (ER) Tablets by Wet Granulation Method. Research Journal of Pharmacy and Technology. 2026;19(4):1675-0. doi: 10.52711/0974-360X.2026.00240 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-4-29
REFERENCES:
1. Kumaravelrajan, R. et al. Novel Paediatric Extended Release Mini-Tablets Formulation and Characterization of Lamotrigine by Design of Experiment (DoE). Research Journal of Pharmacy and Technology. 2024; 17(8): 3649-57. doi: 10.52711/0974-360X.2024.00569
2. Sharma, G. et al. Formulation and evaluation of extended release tablets of Diltiazem hydrochloride. Research Journal of Pharmacy and Technology. 2016; 9(7): 782-8. doi: 10.5958/0974-360X.2016.00150.5
3. Rapeti, D. et al Method Development and Validation for Pyrogallol Content Quantification by HPLC in Trimetazidine Dihydrochloride. Research Journal of Pharmacy and Technology. 2021; 14(11): 5803-7. doi: 10.52711/0974-360X.2021.01009
4. Damle, M. C. et al. A New Stability Indicating HPTLC Method Development and Validation for Estimation of Trimetazidine Dihydrochloride and Metoprolol Tartrate. Asian Journal of Pharmaceutical Analysis. 2025; 15(1). doi: 10.52711/2231-5675.2025.00003
5. Barokar, A. A. et al. Formulation and characterization of taste masked Rapid Disintegrating tablets of Trimetazidine HCl. Research Journal of Pharmacy and Technology. 2011; 4(7): 1098-102.
6. Madathil, S. et al. Formulation and evaluation of fast dissolving tablets of trimetazidine dihydrochloride using natural and synthetic superdisintegrants. Research Journal of Pharmaceutical Dosage Forms and Technology. 2016; 8(2): 95-104. doi: 10.5958/0975-4377.2016.00013.6
7. Tan, D. et al. Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025.
8. Giannoni, A. et al. Pharmacological Treatment of Ischemic Heart Disease. In Ischemic Heart Disease: From Diagnosis to Treatment. Cham: Springer International Publishing. 2023; 1(2): 345-67.
9. Aakif, B. et al. Pharmacogenomics and Drug-Drug Interaction between Amiodarone and Metoprolol. Asian Journal of Pharmaceutical Analysis. 2025; 15(1). doi: 10.52711/2231-5675.2025.00009
10. Dy, A. M. B. et al. Trimetazidine-induced parkinsonism: a systematic review. Frontiers in Neurology. 2020; 11(44).
11. Othman, A. I. et al. Trimetazidine dihydrochloride pulsatile–release tablets for the treatment of morning anginal symptoms: dual optimization, characterization and pharmacokinetic evaluation. Current Drug Delivery. 2021; 18(8): 1194-208.
12. Saraswathi, S. Development of Chronopharmaceutical Drug Delivery System for the Treatment of Angina Pectoris. 2021.
13. Wang, J. et al. Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified‐release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects. Clinical Pharmacology in Drug Development. 2023; 12(2): 212-18.
14. Kamisah, Y., and Che Hassan, H. H. Role of Trimetazidine in ameliorating endothelial dysfunction: a review. Pharmaceuticals. 2024; 17(4): 464.
15. Ge, Y. et al. Direct compression tablet formulation of trimetazidine through systematic screening of oxalate salts. International Journal of Pharmaceutics. 2025; 6(71): 125-255.
16. Sornsuvit, C. et al. Bioequivalence Study of Modified Release Formulations of Trimetazidine 35 mg MR Tablets in Healthy Thai Subjects: Single Dose Under Fasting Condition, Single Dose Under Fed Condition and Multiple Dose Under Fed Condition. J Bioequiv Availab. 2024; 16: 555.
17. Javeer SD et al. Formulation and evaluation of trimetazidine dihydrochloride extended release tablets by melt congealing method. Indian J Pharm Sci. 2010 Nov; 72(6): 704-9. doi: 10.4103/0250-474X.84578. PMID: 21969741; PMCID: PMC3178970.
18. Reddy, Y. K., and Umera, F. Formulation and Evaluation of Sustained release matrix tablets of Atomoxetine HCl by using Natural and Synthetic Polymers. Asian Journal of Pharmacy and Technology. 2020; 10(1): 43-7. doi: 10.5958/2231-5713.2020.00009.4
19. Alkhodri, A. et al. Preparation, Development and Analytical Evaluation of Solid Pharmaceutical Dosage Forms of Nimesulide with Controlled Release and Immediately Release. Research Journal of Pharmacy and Technology. 2025; 18(6): 2725-31. doi:10.52711/0974-360X.2025.00391
20. Phothikun, A. et al. The Effect of Preoperative Oral Trimetazidine on Ischemic Injury and Hemodynamic Function in Coronary Artery Bypass Grafting: A Double-Blinded, Prospective, Randomized Controlled Trial. Journal of the Medical Association of Thailand. 2022; 105(8).
21. USP43-NF38. The United States Pharmacopeial Convention, USA. 2022. Available at: URL: https://www.uspnf.com/notices/usp-43-nf-38-online-table-contents-admissions.
22. Jain, H. K., and Deore, D. D. Development and Validation of Spectrophotometric Method for Determination of Trimetazidine Hydrochloride in Bulk and Tablet Dosage Form. Research Journal of Pharmacy and Technology. 2016; 9(9): 1457-60. doi: 10.5958/0974-360X.2016.00282.1
23. Fard, M. M., and Fard, A. M. Modeling drug release. Eurasian Journal of Science and Technology. 2022; 2(1): 14-33.
24. Suslina, S., and Alkhodri, A. Preparation, evaluation and development celecoxib prolonged release (PR) tablets by using cellulose polyacrylic acid-based polymers. Research Journal of Pharmacy and Technology. 2022; 15(4): 1727-31. doi: 10.52711/0974-360X.2022.00289
25. Sawant, V. A. et al. In-Vitro Release Kinetic Study of Mosapride Citrate Dihydrate from Sustained Release Matrix Tablet Containing Two Different Viscosity Grades of HPMC. Research Journal of Pharmaceutical Dosage Forms and Technology. 2009; 1(3): 207-12.